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Abstract
Hematopoietic  defects  in  HOXA9
-/-  mice  demonstrate  a  key  role  for  this 
homeoprotein in blood cell development. Conversely, enforced HOXA9 expression is 
leukemogenic  in  mice,  and  HOXA9  is  frequently  activated  in  human  acute  myeloid 
leukemia  (AML).  While  HOXA9   i s  thought  to  function  as  a  transcription  factor,  few 
downstream targets have been identified. We searched for early HOXA9 target genes 
by  using  a  transient  over-expression  strategy  in  three  hematopoietic  cell  lines  (2 
myeloid,  1  lymphoid).  cDNA  microarray  analyses  identified  220  genes  whose 
expression  was  modulated  at  least  two-fold.  Expression  signatures  in  myeloid  and 
lymphoid cells demonstrated that HOXA9 functions as both an activator and repressor 
of a variety of genes in cell-specific patterns suggesting that the transcriptional effects of 
HOXA9 are largely cell-context dependent. Transient transcription assays and target 
gene expression patterns in HOXA9
-/- marrow cells imply that we have identified direct 
physiologic targets. Many target genes are expressed in CD34
+ stem cells and/or are 
members of gene families involved in proliferation or myeloid differentiation. Expression 
of  fourteen  HOXA9  target  genes  correlated  with  high  level  HOXA9  expression  in 
primary  AML.  These  data  suggest  that  many  genes  identified  in  this  survey  may 
mediate  the  biologic  effects  of  HOXA9  in  normal  and  leukemic  hematopoiesis. 
jeffl@medicine.ucsf.edu
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Introduction
HOX homeodomain proteins exert important effects during embryogenesis and 
blood cell development.
1-3 As a member of this large family, HOXA9 is expressed in 
normal human CD34
+ blood cells, and is down-regulated during differentiation. HOXA9 -
deficient  mice  display  a  variety  of  myeloid  and  lymphoid  defects.
4,5 HOXA9  over-
expression in bone marrow cells induces marked stem cell expansion, and HOXA9
-/- 
hematopoietic stem cells appear to have a major proliferative defect
6 (Lawrence et al. in 
preparation).
Several studies have established a role for HOXA9 over-expression in myeloid 
leukemogenesis. Cases of AML arising in leukemia-prone BXH2 mice show frequent 
retroviral  activation  of  HOXA9.
7  Retroviral  over-expression  of  HOXA9  immortalizes 
murine  marrow  cells  in  vitro, and  readily  leads  to  leukemic  transformation  in  vivo.
8,9
HOXA9 is also important in human AML, as this gene is activated in most cases of 
acute AML, and a t(7;11) chromosomal translocation resulting in a NUP98-HOXA9  gene 
fusion  is  found  in  some  cases.
7,10  In  a  previous  gene  expression  study  in  human 
leukemia, HOXA9  emerg ed as one of the top 20 genes that distinguished AML from 
ALL, and high levels of HOXA9 expression correlated with poor prognosis.
11,12 Thus, 
HOXA9 expression is part of the gene expression signature for AML, and may also be a 
prognostic factor. 
Several  HOX  genes,  including  HOXA9 ,  are  direct  targe ts  of  the  MLL  (mixed 
lineage  leukemia)  gene,  and  leukemias  associated  with  MLL  translocations  show 
uniform activation of HOXA9.
13-16 The ability of a MLL fusion gene to induce myeloid 
leukemia  in  murine  marrow  cells  requires  the  presence  of  HOXA9,  suggesting  that 
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HOXA9 is a mediator of the transforming effects of MLL fusion proteins.
17 Thus, altered 
HOXA9  gene  expression  may  be  a  common  pathway  that  unifies  diverse  initiating 
events in many myeloid leukemias.
18
Because  HOXA9  exerts  major  biologic  effects  on  normal  and  leukemic 
hematopoiesis,  and  because  very  little  is  known  about  the  molecular  pathways 
regulated by this homeoprotein, we completed a comprehensive gene expression profile 
of  hematopoietic  cells  in  which  HOXA9  was  transiently  over-expressed.  This  study 
reveals that HOXA9 rapidly modulates the expression of a large number of genes that 
are implicated in normal hematopoiesis and in oncogenesis. 
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Materials and Methods
Cell lines
Tet-inducible Jurkat cells were purchased from Clontech (Palo Alto, CA). Tet-inducible 
U937  cells  were  provided  by  Dr.  Gerald  Grosveld.    Tet-inducible  K562  cells  were 
supplied by Dr. Dan Rosson. All Tet-inducible cell lines were maintained in RPMI with 
10%  Tet-free  serum.  NIH3T3  fibroblasts  were  transduced  with  MIG-GFP  or  MIG-
HOXA9/GFP containing MSCV-based retroviruses and maintained in DMEM with 10% 
serum. 
DNA transfections
A Flag epitope tagged HOXA9  cDNA encoding a 246 amino acid protein (accession 
number  NM_010456)  was  cloned  into  the  tet-inducible  vector,  pBI-eGFP  (Clontech), 
yielding  pBI-FlagHOXA9-eGFP.  pBI-eGFP  contains  a  tet-activator  responsive  bi-
directional  promoter  region.  In  the  absence  of  tetracycline,  pBI-FlagHOXA9-eGFP
expresses both Flag-HOXA9 and eGFP proteins. pBI-eGFP (reference control) or pBI-
FlagHOXA9-eGFP  was  electroporated  into  tet-activator  expressing  U937,  K562  and 
Jurkat cells. All studies were performed using transient transfections in the absence of 
tetracycline, coupled with FACS sorting of eGFP+ cells 24 hours after transfection. Two 
independent eGFP
+ transfections and sorts were performed for each cell line to yield 
biological replicates. HOXA9 protein expression was verified by Western blot analysis 
with an anti-HOXA9 antibody. 
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RNA amplification
Total RNA from sorted cells was isolated with the RNeasy Mini kit (Qiagen, Valencia, 
CA). mRNA in one µg of total RNA was amplified 5-20 fold as previously described.
19
Briefly, mRNA was reverse transcribed into cDNA using an oligo-dT-T7 primer and was 
subsequently converted to double stranded cDNA. T7 RNA polymerase was used to 
generate a pool of amplified RNA.
cDNA microarrays
A 44,022  human  cDNA  clone  set,  purchased  from  Research  Genetics  (Invitrogen, 
Carlsbad, CA) was printed onto two poly-L-lysine coated glass slides (approximately 
20,000  genes  per  slide)  and  post-processed  following  protocols  listed  at 
http://www.microarrays.org/pdfs/PostProcessing2001.pdf. To control for variability between 
the two samples, HOXA9- (reference) samples were cultured, transfected and sorted 
simultaneously with the HOXA9+ samples with which they were hybridized. Two µg of 
amplified mRNA from HOXA9
- and HOXA9
+ samples from the same transfection/sorting 
experiment were labeled with Cy3 or Cy5 respectively and combined for hybridization to 
microarrays.
20  In  addition  to  performing  biological  replicate  hybridizations  from  two 
independent  sorting  experiments,  the  third  hybridization  represented  a  technical 
replicate,  which  consisted  of  independently  labeled  RNA  samples  from  one  of  the 
eGFP+ sorting experiments. Arrays were hybridized overnight in a 63
oC water bath and 
washed  twice  with  2X  SSC/0.01%SDS  and  once  with  0.5XSSC.  The  slides  were 
scanned  with  a  dual-laser  Axon  Instruments  4000B  Scanner  using  GenePix  4.0 
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From 7
software. Images for the Cy5 and Cy3 channels were acquired separately. Spots that 
were covered by array or hybridization artifacts were manually flagged and were not 
used  in  subsequent  analyses.  GenePix  results  files  containing  ratio  of  medians 
measurements,  calculated  as  Cy5/Cy3,  were  uploaded  to  the  NOMAD  microarray 
database for storage and normalization. NOMAD is a database that is used to archive 
microarray GenePix results (.gpr) files. This “warehouse” is an open source system for 
storing  and  querying  microarray  experiments.  For  further  details  go  to 
http://sourceforge.net/projects/ucsf-nomad/.
Microarray Analysis
When microarray .gpr files were uploaded to NOMAD, normalized fluorescence 
ratios were calculated. Signal intensities between the two Cy5 and Cy3 images were 
normalized by applying a scaling factor to all of the Cy5 channel values so that the 
mean of ratios = 1.
21 Spot quality was assured by inclusion of data points where R
2 > 
0.75. Next, a table of microarray data containing rows of genes and columns of data 
points from individual experiments was created in NOMAD. This file was opened in the 
CLUSTER program, and data points were log2 transformed and filtered. After average 
linkage  hierarchical  clustering  was  performed,  values  in  the  resulting  .cdt  file  were 
visualized by TREEVIEW software.
22 Statistical significance of the microarray data was 
assessed by SAM, Statistical Analysis for Microarrays, a t-test permutation algorithm.
23
The input parameters used for this analysis were: row average imputer and one class 
response.
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RT-PCR validation
EPS8, EST AA789015, MYB, TCN1, LYN and GAPDH transcript levels were detected 
in amplified RNA from K562 transfected cells by standard RT-PCR. PCR products were 
visualized on ethidium bromide-stained agarose gels. Fold difference was calculated 
from densitometric values of PCR product intensities from PCR cycles within the linear 
range. ALDH1 and JUNB transcripts were detected by a one-step quantitative real-time 
RT-PCR method with Taqman fluorogenic probes.
24
VHL,  ID2,  MBNL,  SFRS11,  and  CD36  expression  levels  were  measured  in 
amplified RNA from each cell line, and expression was quantified using real-time PCR 
with SYBR Green. Annealing and acquisition temperatures were determined empirically 
from  dissociation  curves.
25  Fold  differences  for  all  real-time  PCR  experiments  were 
calculated using the 2
-￿￿CT method.
26
Luciferase reporter vector cloning and assays
A 1 Kb fragment of the human ALDH1 promoter was PCR amplified from a 2.5 Kb 
fragment an ALDH1 promoter-containing vector provided by Dr. Fred Gonzalez. A 1 Kb 
region  of  the  human  CD36  promoter  was  PCR  amplified  from  genomic  DNA.  PCR 
products  were  cloned  into  the  PCR2.1  TOPO  T/A  cloning  vector  and  then  into  the 
pGL3-enhancer vector. 
Reporter  and  expression  plasmids  were  transfected  with  Lipofectamine  2000 
(LF2000).  Two  µg  of  plasmid  DNA  (1µg  pBI-GFP  or  pBI-HOXA9/GFP  and  1  µg  of 
reporter vector) were added to 4 µl of LF2000 and incubated with 6 X 10
5  K562or U937
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cells, or 7.5 X 10
5 Jurkat cells in 24 well plates. Cells were harvested 48 hours later and 
lysed in Luciferase Assay Reagent (Promega, Madison, WI). Reporter light units were 
measured in a Monolight 2010 Luminometer.
Mouse bone marrow
Marrow cells from the tibias and femurs of HOXA9
-/- mice and wild-type controls were 
enriched for Lin
- Sca
+ immature progenitors using the Spin-Sep technique (Stem Cell 
Technologies, Vancouver, BC).
5 RNA was isolated, and 1 µg was amplified following 
the protocol described above. Real-time PCR was performed for JUNB and EPS8 using 
SYBR Green. 
Patient samples
Total RNA was isolated from 11 cryopreserved bone marrow samples of de novo AML, 
provided by the UCSF Leukemia Cell Bank. Relative expression levels of HOXA9 and 
JUNB were compared to GAPDH, as measured by real-time PCR. 
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Results
Gene expression profiling of early HOXA9 gene targets
To  identify  primary  HOXA9  target  genes  in  hematopoietic  cells  we  used  a 
transient, FACS-selectable expression system coupled with cDNA microarrays. Three 
human  leukemic  cell  lines,  two  myeloid  (U937,  myelomonocytic,  and  K562, 
erythroid/megakaryocytic)  and  one  lymphoid  (Jurkat,  T-cell),  were  analyzed.    While 
U937 cells express measurable levels of HOXA9 mRNA, K562 and Jurkat cells do not
10
(and unpublished data).
Plasmids  overexpressing  eGFP  alone  or  eGFP  with  an  IRES-driven  HOXA9
cDNA were transiently transfected into each cell line. Cells were harvested 24 hours 
later and sorted for eGFP positivity. High levels of HOXA9 mRNA and protein in cells 
transfected with the HOXA9 vector were confirmed by real-time PCR and Western blot 
analyses  (data  not  shown  and  Figure  1A).  mRNA  from  the  HOXA9
-  and  HOXA9
+
samples was amplified by in vitro transcription (IVT), and labeled with Cy3 and Cy5 
respectively.  The  two  samples  were  combined  and  hybridized  to  large-scale  cDNA 
microarrays. IVT amplification fidelity, comparing unamplified to amplified RNA samples, 
and  array  hybridization-to-hybridization  reproducibility  of  independently  amplified 
samples were 75% and 85% respectively, as measured by the R
2 correlation coefficient. 
To  decrease  the  percentage  of  misclassifications,  triplicate  microarray  hybridizations 
were performed for each cell line.
27
CLUSTER software was used to filter the microarray data for each cell line. This
analysis created a list of 220 genes that were modulated at least 2 fold. Selected named 
genes enumerated by these criteria are arranged in functional groups in Table 1. The 
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classes of genes represented included signaling molecules, oncogenes, kinases, cell 
surface  molecules,  enzymes  and  other  transcription  factors.  90  ESTs  were  also 
identified (data not shown). More genes were modulated in the U937 and K562 cells 
(132 and 106 genes) than in the Jurkat cells (41 genes).  In the two cell lines that lack 
detectable  endogenous  HOXA9,  K562  and  Jurkat,  HOXA9  upregulated  more  genes 
than it downregulated (68 genes up vs. 38 genes down in K562; 23 genes up vs. 18 
genes  down  in  Jurkat).  However,  in  U937,  HOXA9  overexpression  induced  the 
upregulation  of  36  genes,  but  downregulated  96  genes.  Thus,  HOXA9  appears  to 
modulate many genes, acting both as an activator and a repressor
Next,  we  performed  another  analysis  with  the  CLUSTER  software  using 
microarray data from all three cell lines to compare expression patterns between the 
different cell lines. This pattern was then manually divided into smaller groups based on 
differential target regulation in myeloid vs. lymphoid backgrounds (Figure 1B, groups I-
V). Many genes showed up-regulation in myeloid, and either no expression or down-
regulation  in  lymphoid  cells,  suggesting  that  the  transcriptional  effects  of  HOXA9 
depend largely on cellular context (groups II, III and IV). A few genes were regulated in 
the  same  manner  in  all  three  lines,  indicating  that  transcription  of  some  targets  is 
modulated in a cell context-independent fashion (groups I and IV). The EST AA789015 
and PKNOX1 were up-regulated, and three ESTs (AI243377, AI299780 and AI243380) 
were  down-regulated  in  all  three  lines. Figure  1C  presents  genes  that  showed  the 
greatest degree of change in each cell line. 
We  also  used  the  significance  analysis  of  microarrays  algorithm,  SAM,
23  to 
analyze the microarray data for each cell line. Most of the genes previously highlighted 
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by  the  CLUSTER  analysis,  174  out  of  220  (79%),  were  shown  to  be  significantly 
changed by HOXA9 over-expression, and are italicized in Figure 1C. All of the genes 
listed in Tables 1 and 2 were significant as determined by SAM analysis, except where 
indicated. 
Validation of HOXA9 targets identified by microarray analysis
Of the 48 genes that were expressed in a similar manner in more than one cell 
line,  nine  were  chosen  for  validation  by  RT-PCR  in  K562  cells. We  selected  genes 
involved in malignant transformation, such as JUNB and EPS8, the stem-cell specific 
gene  ALDH1,  which  also  plays  a  role  in  drug  resistance,
28  and  genes,  such  as 
transcobalamin  1  (TCN1),  CD36,  MYB,  ID2  and  LYN,  that  have  been  previously 
detected  in  myeloid  cells.  The  direction  of  each  gene's  change  in  expression  as 
determined by microarray was confirmed by RT-PCR (Figure 2A). The array data also 
suggested that HOXA9 can modulate the same gene in opposite directions in different 
cell lines. Of the 12 genes that were differentially regulated between cell lines, three 
were chosen for further analysis. Figure 2B shows real-time PCR data confirming this 
phenomenon for MBNL, SFRS11 and VHL . In 15 out of 16 (94%) comparisons of gene 
expression levels by the two methods, the direction of change seen by RT-PCR was 
consistent with changes observed on the microarrays.  
To determine if genes identified in this survey were direct targets of HOXA9, we 
performed luciferase reporter gene analysis of the ALDH1 and CD36 promoters (Figure 
3).
29  For  ALDH1,  we  observed  that  HOXA9  over-expression  increased  transcription 
from this promoter 1.6 and 2.4 fold in U937 and K562 cells respectively, but down-
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regulated transcription 2.4 fold in Jurkat cells. Analysis of the HOXA9 responsiveness of 
the  CD36  promoter  showed  down-regulation  by  HOXA9  by  2.3,  1.9  and  4.4  fold  in 
U937, K562 and Jurkat cells, respectively. For both genes, the effect of HOXA9 on the 
promoter driven reporter activity paralleled the changes in mRNA levels detected by 
microarray and RT-PCR.
To analyze whether HOXA9 gene targets identified in myeloid cell lines were also 
targets in other cell types, JUNB and EPS8 mRNA levels were assessed in NIH3T3 
fibroblasts  stably  transduced  with  a  HOXA9  expression  vector.  Figure  4A  shows 
HOXA9 expression is increased over 100 fold in the transduced cells as compared with 
parental  cells.  Consistent with  the  changes  seen  in  K562  cells, JUNB  expression  is 
decreased and EPS8 expression is increased in HOXA9 over-expressing cells. If these 
two genes are authentic targets of HOXA9 in hematopoietic cells, we reasoned that 
their expression levels would be altered in marrow cells from HOXA9 - deficient mice. 
Figure 4B shows JUNB and EPS8 expression levels in immature precursor enriched 
bone marrow cells of control and HOXA9
-/- mice. JUNB expression is increased by 60 
fold, whereas EPS8 expression is decreased 8 fold, thus exhibiting the converse of the 
changes observed in HOXA9  over -expressing cell lines. 
HOXA9 target expression in CD34
+ stem cells
To discern which HOXA9 target genes identified in this microarray analysis were 
involved  in  normal  stem  cell  biology,  we  searched  the most  comprehensive,  current 
database of CD34
+ human bone marrow cells, The Human Stem Cell Transcriptome 
Database (http://westsun.hema.uic.edu/cd34.html).
30 The expression of 36 genes that 
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are activated by HOXA9 and 42 genes that are repressed by this homeodomain protein 
were  detected  in  CD34
+  cells  from  low  to  very  high  expression  levels  (Table  2).  In 
addition  to  confirming  HOXA9  expression,  this  database  reported  that  several 
uncharacterized  HOXA9  targets,  including  EST  AA789015,  are  expressed  in  CD34
+
stem  cells  (highlighted  in  blue  in  Figure  1C).  These  data  indicate  that  HOXA9  can 
modulate  a  number  of  characterized  and  uncharacterized  genes  involved  in  normal 
stem cell function.
Analysis of HOXA9 targets in AML
AML  is  a  heterogeneous  disease  that  can  result  from  different  chromosomal 
abnormalities, and HOXA9  mRNA levels, although elevated in most cases, vary within 
this  disease.  Therefore,  to  determine  if  any  candidate  HOXA9  gene  targets  were 
similarly altered in primary AML samples with high HOXA9 levels, we performed an in 
silico  analysis  of  the  Affymetrix  GeneChip  dataset  published  by  Armstrong  et  al..
16
These AML patient samples were divided into high and low HOXA9-expressing groups 
based on their HOXA9 mRNA expression levels (Figure 5A). Average gene expression 
levels were calculated for all genes and these values were compared between the two 
groups. Ten HOXA9 targets are upregulated and 4 are downregulated in a manner that 
correlates  with HOXA9  expression.  In  addition,  JUNB  expression  was  confirmed  by 
real-time PCR in a separate set of AML patient samples, and was shown to be inversely 
related to HOXA9 expression with a 2 fold lower level of expression in the high HOXA9 
group as compared to the low HOXA9 group (Figure 5B). Thus, fourteen (10%) of the 
named  genes  that  were  up-  or  down-regulated  by  HOXA9  in  our  transient  over-
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expression study are similarly modulated in primary AML samples. While many of the 
other  target  genes  were  either  not  represented  on  the  GeneChip  or  were  not 
differentially regulated, a few were regulated in the opposite direction. However, it was 
not  our  expectation  that  the  transcriptome  of  HOXA9-tranfected  cell  lines  would 
necessarily completely overlap with the transcriptome of primary AML, given the array 
of genetic mutations in this disease. Rather, we posit that areas of overlap represent 
genes worthy of further study.
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Discussion
A major finding of this study is that activation of HOXA9 can rapidly modulate the 
expression  of  a  large  group  of  genes,  representing  a  wide  variety  of  functional 
categories not previously known to be targets of any HOX gene.  Real-time PCR and/or 
SAM  analysis  confirmed  a  large  percentage  of  these  changes,  and  transient 
transcription assays suggest that at least some of these genes are direct targets of 
HOXA9.  This  study  also  provides  insights  concerning  the  general  transcriptional 
function of HOX genes by confirming that they can act as activators and repressors of 
gene transcription.
31,32 We also demonstrate that a human HOX gene can positively or 
negatively  regulate  a  given  gene,  depending  on  cellular  context,  as  previously 
recognized in Drosophila.
33 Importantly, we also report that many of the HOXA9 targets 
we identified are expressed in CD34+ stem cells, where HOXA9 is expressed during 
normal blood cell development.  We also showed that some HOXA9 target genes are 
dysregulated in primary samples of human AML and correlate with HOXA9 expression 
in this disease.
In  addition,  we found  some  HOXA9  targets  that  undergo  expression  changes 
during myeloid differentiation as demonstrated by gene expression profiling analyses of 
U937 and NB4 cells -/+ retinoic acid.
34,35 These experiments revealed changes in a 
variety  of  gene  families,  including  transcription  factors,  cytoskeletal  and 
transcription/translation associated proteins. As HOXA9 is expressed in CD34
+ cells,
4
and its expression decreases as cells mature, we surmised that the expression pattern 
of some of its targets may be reversed during differentiation. Indeed, examination of 
these published datasets showed that VIM, MYB, GTFIIB and ribosomal genes which 
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are  upregulated  by  HOXA9  in  our  over-expression  study,  are  down-regulated  upon 
differentiation, and ID2, WSB-1 and S100A8 which are down-regulated by HOXA9 in 
our study, are up-regulated as differentiation progresses. In the HL60 cell line, vitamin 
D,  retinoic  acid  and TPA-induced  differentiation  showed  changes  for  small  inducible 
cytokines,  including  MIP1A,  which  is  upregulated  in  differentiation,  yet  repressed  by 
HOXA9  in  our  experiments.
36-38  Lastly,  MAFB  induction  is  critical  for  monocytic 
differentiation, and HOXA9 may aid in keeping cells in an immature state by repressing 
this gene in CD34+ cells.
39
Other candidate HOXA9 targets play roles in embryonic development such as 
NLK, IRX-3 and NFIA.  NLK, the vertebrate homolog of the Drosophila gene, nemo, has 
been shown to have diverse roles in signaling during development, and plays a role in 
organismal patterning.
40 Expression of IRX-3, a member of the Iroquois homeodomain 
family, is also expressed during embryonic development, and has recently been shown 
to be a putative target of HOXA3.
41,42 The expression pattern of nuclear factor IA during 
mouse embryogenesis points to its potential role for this gene in development.
43
Among  other  targets  identified,  several  emerge  as  potential  mediators  of 
HOXA9’s leukemogenic effects, including genes involved in cell cycle regulation and 
proliferation. For example, CDC6 and CDK7 were up-regulated in myeloid cells over-
expressing  HOXA9.  Cdc6  has  been  reported  to  bind  to  chromatin  and  aid  in  the 
initiation of DNA replication and cell proliferation.
44 Cdk7 mediates several processes 
including  cell-cycle  control  and  transcriptional  regulation.
45  In  addition,  increased 
expression  of  ribosomal  proteins,  elongation  factors,  RNA  splicing  factors  and  RNA 
helicases  was  identified  in  a  proliferation  cluster  of  genes  that  was  associated  with 
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From 18
increased doubling time in cell lines analyzed by Ross et al..
21 Members of these gene 
families were also upregulated by HOXA9, such as RPL27a, RPS3a, HNRPU, DDX8, 
DDX36, ADD3 and SFRS11.
Some genes that are repressed by HOXA9 have tumor suppressor functions. 
JUNB and LYN were both down-regulated by HOXA9 in the myeloid cells tested. Loss 
of JUNB in mice results in a myeloproliferative syndrome that resembles CML, and is 
associated with up-regulation of anti-apoptotic bcl-2 and bcl-xl proteins.
46 LYN-deficient 
mice  display  increased  numbers  of  myeloid  progenitors  and  develop 
monocyte/macrophage  tumors.
47  While  the  VHL  gene  was  also  shown  to  be 
downregulated by HOXA9 in myeloid cells, a connection between this gene has been 
associated  with  other  cancers,  and  we  report  that  its  expression  is  not  detected  in 
HOXA9-high expressing AML samples.
Conversely, several oncogenes, including MYB, and two Ras family members, 
EPS8 and RAP1B, were up-regulated in the myeloid cell lines analyzed.  MYB over-
expression transforms cells in culture and results in acute leukemia in animals.
48 EPS8
and RAP1B have transforming potential when overexpressed in NIH 3T3 fibroblasts.
49,50
Other HOXA9 target genes that were grouped into a leukemia cluster by Ross et al. are 
PTPRC  and  ETS2.
21 ETS2  has  been  previously  shown  to  participate  in  t(8;21) 
translocations  in  AML-M2.
51  In  addition,  several  other  HOXA9  targets  have  been 
previously  associated  with  leukemia  such  as  HOXB2,  MBNL  (KIAA0428)  PIM-1, 
HMG17,  and  RPS3A  (FTE1).
14,16,52-54  Thus  several  potentially  oncogenic  pathways 
appear  to  be  modulated  by  HOXA9  and  may  therefore  mediate  its  leukemogenic 
effects.  Further  support  for  the  roles  of  HOXA9  targets,  such  as  EPS8,  RPS3A  or 
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TACC1, as oncogenes lies in the fact that their expression was not detected in CD34
+
stem cells, which may mean that their expression is the result of aberrant activation of 
HOXA9 in primitive myeloid cells. However, other oncogenes that have been previously 
shown to be dysregulated in leukemia are also expressed in stem cells, such as ETS2, 
HMG17 and PIM1, suggesting that further research on the expression of these genes is 
required.
While HOXA9 appears to regulate a variety of genes, the same phenomenon has 
been observed for other transcription factors and oncogenes such as Myc, Myb and 
Ras.
55-57  Over-expression  strategies  of  these  proteins  has  shown  that  they  also 
modulate many genes with vastly different functions. Some shared targets been HOXA9 
and RAS include YES, RAP1B, MAN2A1, SDC4 and VIM.  RPL27a, JUNB, ID2, ETS2, 
VHL  and  JUN  are  targets  that  are  shared  between  HOXA9  and  MYC.  Targets  in 
common between MYB and HOXA9 are transcription/translation associated proteins, 
small inducible cytokines and cytoskeletal genes.
Lastly, some of the HOXA9 targets identified have been shown to be targets or 
family members of targets of other HOX genes in other cell systems. For example, in 
the instances of RAP1B and IRX-3, HOXB4 has been shown to regulate RAP1 and IRX-
5.
58,59 A study of MLL target genes showed that IRX-3 was downstream of this protein, 
presumably  through  a  HOX  gene.
60  Over-expression  of  HOXD3  showed  that  it  also 
regulates  VIM,  as  well  as  syndecan  1,  RAB13  and  several  keratins.
31  HOXC13 
overexpression in murine skin also regulates several keratin-associated proteins and 
14-3-3 beta.
61  Comparison  of  HOXA9  and HOXA13  gene  targets  revealed  that  they 
both regulate small inducible cytokines and 14-3-3 proteins.
62 Nonetheless, the genes 
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showing  the  largest  and  most  consistent  changes  in  expression  following  HOXA9 
activation  are  ESTs  of  unknown  function,  suggesting  that  several  important  HOXA9 
target genes are as yet uncharacterized.
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SIGNALING M OLECULES UKJ KINASES AND P HOSP HATASES UKJ
ARF1 ADP-ribosylation factor 1      CSNK1A1 casein kinase 1 , alpha 1 ,CK1
ARHGAP 11A GTPase-activating protein rhoGAP, KIAA001 3 INP P L1 inositol pholyphosphate phosphatase-like 1 , SHIP2
ARL3 ADP-ribosylation factor-like 3           NLK nemo-like kinase
CISH cytokine-inducible SH2-containing protein
EP S8 EGFR pathway substrate 8             SECRETED M OLECULES
GNG10 guanine nucleotide binding protein 1 01 HBE1 hemoglobin epsilon 1  
GTP BP 1 GTP binding protein 1 IGF2 insulin-like growth factor 2 , somatomedin A1
M AP 4K5 mitogen-activated protein kinase kin. kin. kin. 5  M IP 1A small inducible cytokine A3, CCL3, SCYA3 2
RAP 1B member of RAS oncogene family2 TCN1 transcobalamin I vitamin B1 2 binding protein
WSB1 SOCS box-containing WD protein SWiP-1 , isoform 1
YWHAG 1 4-3-3 gamma,  tyrosine 3/5-monooxyg. activ. prot. TRANSCRIP TION FACTORS
CREM cAMP responsive element modulator
ONCOGENES AND TUM OR SUP P RESSORS ETR101 immediate early protein
BM I1 murine leukemia viral (bmi-1 ) oncogene homolog  GATA2 GATA-binding protein 2
ETS2 v-ets erythroblastosis virus E26 oncogene  homolog 2 GFT2B general transcription factor IIB, TFIIB
JUN v-jun sarcoma virus 1 7 oncogene homolog1 HOXB2 homeobox B22 
JUNB jun b protooncogene1 ID2 inhibitor of DNA binding 2 
LYN v-yes-1  Yamaguchi sarcoma viral oncogene homolog1 IRX3 iroquois class homeodomain protein 3
M AFB Kreisler maf-related leucine zipper homolog, KRML 2 NFIA nuclear factor I/A
M AFG v-maf musculoaponeurotic fibrosarcoma oncogene G P KNOX1 PBX/Knotted 1  homeobox 1 , PREP1
M YB v-myb myeloblastosis viral oncogene homolog2 ZFP 103 zinc finger protein 1 03, KF1
M YC v-myc myelocytomatosis viral oncogene homolog
P IM 1 pim-1  oncogene RNA AND DNA P ROCESSING, BINDING P ROTEINS
ST13 suppression of tumorigenicity 1 3 CUGBP 1 CUG triplet repeat, RNA-binding protein 1
TACC1 transforming, acidic coiled-coil containing protein2 CUGBP 2 elav-type , RNA-binding protein 2
VHL von Hippel-Lindau syndrome, tumor suppressor gene  DDX8 DEAD/H box polypeptide 8 (RNA helicase)2
XTP 2 HBxAg transactivated protein 2  DDX36 DEAD/H box polypeptide 36 (RNA helicase)2
YES1 v-yes-1  Yamaguchi sarcoma viral oncogene 1 FXR1 fragile X mental retardation, autosomal homolog 1
HNRP U heterogeneous nuclear ribonucleoprotein U2
CELL CYCLE P ABP N1 poly(A)-binding protein, nuclear 1
CDC6 cell division cycle 6 homolog2 SFRS11 splicing factor, arginine/serine-rich 1 1
CDC37 cell division cycle 37
CDK7 cyclin-dependent kinase 7, cdk-activating kinase1 TRANSLATION, P ROTEIN P ROCESSING, P ROTEOLYSIS
RP L27A ribosomal protein L27a
M EM BRANE P ROTEINS RP S3A ribosomal protein S3A, FTE1 2
CD36 collagen thrombospondin, platelet glycoprotein IV S100A8 S1 00 calcium-binding protein A8 , calgranulin A2
CLCN7 chloride channel 7 SERP INB9 protease inhibitor 9, clade B
CLIC2 chloride intracellular channel 2  SRP 72 signal recognition particle 72 KD protein 
CLTC clathrin heavy polypeptide (Hc)
EBI2 EBV lymphocyte-specific G-receptor 2 CYTOSKELETAL COM P ONENTS
FCGRT Fc fragment of IgG, receptor, transporter, alpha ADD3 adducin 3 (gamma) 
FP RL1 formyl peptide receptor-like 1 , ALXR,  ARP C5 actin related protein 2/3 complex 
P TP RC protein tyrosine phosphatase, receptor type, c, CD45 2 DNCLI2 dynein, cytoplasmic, light intermed. polypeptide 21
SDC4 syndecan 4, amphiglycan, ryudocan KRT18 keratin 1 8
SDCBP syndecan binding protein , syntenin NEB nebulin
TRAP 240 thyroid hormone receptor-associated protein  VIM vimentin2
ENZYM ES OTHERS
ACHYL1 S-adenosylhomocysteine hydrolase-like 1 CALB1 calbindin
ALDH1A1 aldehyde dehyrogenase 1 , soluble CAP 350 centrosome-associated protein 350, KIAA0480
CBP 2 carboxypeptidase B2 (plasma), CPU, TAFI 1 DLG7 discs, large homolog 7 (Drosophila ) 
CTH cystathionase DSIP I delta sleep inducing peptide, immunoreactor 
DCT dopachrome tautomerase  KRM P 1 M-phase phosphoprotein 1 , MPHOSPH1
GLRX glutaredoxin, thioltransferase  OSBP L8 OSBPL8 oxysterol binding protein-like 8
LYZ lysozyme  RBBP 6 retinoblastoma-binding protein 6, RBQ-1 1
M AN2A1 mannosidase, alpha, class 2A, member 1 TDE2 tumor differentially expressed protein 2 
M AN2A2 mannosidase, alpha, class 2A, member 2
P CM T1 protein- carboxyl methyltransferase 1
USP 1 ubiquitin-specific protease 1 Degree of M odulation by HOXA9
>5 fold upregulated
NUCLEAR P ROTEINS 3-5 fold upregulated
CBX6 chromobox homolog 61 2-3 fold upregulated
HM G17 high-mobility group protein 1 72 >5 fold downregulated
M BNL muscleblind-like (Drosophila ), KIAA0428 3-5 fold downregulated
TP R translocated promoter region 2-3 fold downregulated
1, genes that were represented by more than one spot/accession number. 2, genes that were modulated by HOXA9 as determined by the CLUSTER 
analysis, but were not classified as statistically significant as determined by the parameters set in the SAM analysis.
Table 1.  Functional classification of selected HOXA9 target genes
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Table 2. HOXA9 target genes that are expressed in CD34+ stem cells.
Downregulated by HOXA9 Upregulated by HOXA9
TRAP 240 thyroid hormone receptor-associated protein  P IM 1 pim-1  oncogene
SDC4 syndecan 4, amphiglycan, ryudocan TDE2 tumor differentially expressed protein 2 
LYZ lysozyme (renal amyloidosis) ARL3 ADP-ribosylation factor-like 3          
M AN2A2 mannosidase, alpha, class 2A, member 2 RAP 1B member of RAS oncogene family
JUN v-jun avian sarcoma virus 1 7 oncogene homolog  DDX8 DEAD/H box polypeptide 8 (RNA helicase)
JUNB jun b protooncogene  M AN2A2 mannosidase, alpha, class 2A, member 2
SERP INB9 protease inhibitor 9, clade B JUN v-jun avian sarcoma virus 1 7 oncogene homolog 
GATA2 GATA-binding protein 2 NLK nemo-like kinase
CISH cytokine-inducible SH2-containing protein YES1 v-yes-1  Yamaguchi sarcoma viral oncogene 1
YWHAG 1 4-3-3 gamma,  tyrosine 3/5-monooxyg. activ. prot., gamma  VIM vimentin
FP RL1 formyl peptide receptor-like 1 , ALXR GTP BP 1 GTP binding protein 1
M YC v-myc avian myelocytomatosis viral oncogene homolog RAB31 member of RAS oncogene family, GTP binding protein
CDC37 cell division cycle 37 CUGBP 1 CUG triplet repeat, RNA-binding protein 1
DNCLI2 dynein, cytoplasmic, light intermediate polypeptide 2 CTH cystathionase (cystathionine gamma-lyase)
WSB1 SOCS box-containing WD protein SWiP-1 , isoform 1 ETS2 v-ets avian erythroblastosis virus E26 oncogene  homolog 2
FXR1 fragile X mental retardation, autosomal homolog 1 HM G17 high-mobility group (nonhistone chromosomal) protein 1 7
SFRS11 splicing factor, arginine/serine-rich 1 1 GNG10 guanine nucleotide binding protein 1 0
CD36 collagen thrombospondin, platelet glycoprotein IV SFRS11 splicing factor, arginine/serine-rich 1 1
CLCN7 chloride channel 7 CALB1 calbindin
FCGRT Fc fragment of IgG, receptor, transporter, alpha ALDH1A1 aldehyde dehyrogenase 1 , soluble
SDCBP syndecan binding protein (syntenin) P CM T1 protein- carboxyl methyltransferase 1
ACHYL1 S-adenosylhomocysteine hydrolase-like 1 M AFG v-maf musculoaponeurotic fibrosarcoma oncogene G
DCT dopachrome tautomerase dopachrome delta-isomerase M YB v-myb avian myeloblastosis viral oncogene homolog
GLRX glutaredoxin (thioltransferase)  HNRP U heterogeneous nuclear ribonucleoprotein U
USP 1 ubiquitin-specific protease 1 INP P L1 inositol pholyphosphate phosphatase-like 1 , SHIP2
BM I1 murine leukemia viral (bmi-1 ) oncogene homolog  ZFP 103 zinc finger protein 1 03, KF1
LYN v-yes-1  Yamaguchi sarcoma viral oncogene homolog CDK7 cyclin-dependent kinase 7  (cdk-activating kinase) 
VHL von Hippel-Lindau syndrome, tumor suppressor gene  RP L27A ribosomal protein L27a
DSIP I delta sleep inducing peptide, immunoreactor  ADD3 adducin 3 (gamma) 
OSBP L8 OSBPL8 oxysterol binding protein-like 8 ARP C5 actin related protein 2/3 complex 
RBBP 6 retinoblastoma-binding protein 6, RBQ-1 OSBP L9 oxysterol binding protein-like 9 
TP R translocated promoter region ACHYL1 S-adenosylhomocysteine hydrolase-like 1
KRT18 keratin 1 8 ARHGAP 11A GTPase-activating protein rhoGAP 
S100A8 S1 00 calcium-binding protein A8 (calgranulin A) ST13 suppression of tumorigenicity 1 3 (Hsp70 interacting protein) 
SRP 72 signal recognition particle 72 KD protein  P KNOX1 PBX/Knotted 1  homeobox 1 , PREP1
M OP 3 member of PAS superfamily 3, ARNTL
NFIA nuclear factor I/A Level of expression in CD34+ stem cells
HBE1 hemoglobin epsilon 1   Very high (>1 00)
IGF2 insulin-like growth factor 2 (somatomedin A) High (25-1 00)
M IP 1A small inducible cytokine A3, CCL3, SCYA3 Moderate (1 0-25)
P IM 3 serine threonine kinase, KID-1 , MG61 , porcupine Low (0-1 0)
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From 29
Figure Legends
Figure 1.  Gene expression profiling of early HOXA9 gene targets.
(A) Western blot analysis shows HOXA9 protein expression in transfected U937, K562 
and Jurkat cell lines 24 hours post-transfection with GFP (HOXA9
-) or GFP/HOXA9 
(HOXA9
+) expression vectors. 
(B) Comparison of HOXA9-modulated transcript expression patterns between cell lines 
utilizing Eisen’s hierarchical cluster analysis.
22 The cluster contains 141 known genes 
with a minimum of three data points that were at least 2.5 fold up- or down - regulated. 
Red indicates induction, and green indicates repression. Gray indicates excluded data, 
and  black  indicates  no  change.  Genes  were  grouped  into  smaller  clusters  showing 
similar expression patterns: I. up-regulated in all three cell lines, II. up in myeloid, no 
change in lymphoid; III. up in myeloid, down in lymphoid, IV. down in all three cell lines, 
and V. down in myeloid, up in lymphoid. ￿=AA789015, ￿=AI234380, ￿=AI299780.
(C) Genes exhibiting the greatest magnitude of change by HOXA9 in each cell line. 
Red indicates gene activation, while green indicates repression in at least two out of 
three experiments. Gene names that are highlighted in blue were detected in CD34
+
stem  cells.
63  Names  of  genes  or  ESTs  that  were  identified  as  being  statistically 
significant by the SAM algorithm are italicized. For U937 and K562 cell lines, the false 
discovery  rate  (FDR)  was  set  at  10%.  For  the  Jurkat  cell  line,  the  FDR  was  46%. 
￿=AA789015, ￿=AI234380, ￿=AI299780.
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Figure 2. RT-PCR Validation of selected HOXA9 gene targets.
(A) Confirmation of HOXA9-regulated genes in K562 cells. Gene expression levels were 
calculated  by  normalizing  PCR  data  from  HOXA9
-  and  HOXA9
+  samples  to  control 
genes  as  described  in  Materials  and  Methods.  Fold  up-  or  down-regulation  was 
calculated using the ratio of HOXA9
+/HOXA9
- normalized PCR values and the mean of 
ratios  of  HOXA9
+/HOXA9
-  signals  from  the  microarray  data.  *No  expression  was 
detected in one of the HOXA9 conditions such that the ratio could not be calculated, 
and a lower limit of differential expression is reported. 
(B) Quantitative verification of differential expression of HOXA9 target genes in different 
cell  lines.    Expression  of  three  genes  was  analyzed  by  real-time  RT-PCR,  and  fold 
changes  in  expression  are  expressed  as  the  ratio  of  GAPDH-normalized 
HOXA9
+/HOXA9
- values. Fold changes from the arrays represent the mean values from 
at least two hybridizations.
Figure 3. Reporter gene analysis of HOXA9 target promoters in all three cell lines.
Luciferase reporter plasmids contain the following promoter regions: ALDH1 promoter  
(-980 to +23); CD36 promoter, (-1129 to +36). 
Figure 4.  Putative HOXA9 gene target expression in other cell types. 
(A) JUNB and EPS8 expression levels are modulated by HOXA9 in NIH3T3 fibroblasts. 
HOXA9, JUNB and EPS8 expression levels were measured in RNA from parental cells 
and stably transduced HOXA9 over-expressing cells by real-time PCR. 
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(B) Confirmation of converse changes of EPS8 and JUNB in HOXA9 - deficient murine 
marrow  cells.  Marrow  cells  were  isolated  from  adult  HOXA9
-/-  mice  and  wild-type 
(control) littermates and enriched for Lin- Sca+ primitive cells. HOXA9 ,  JUNB and EPS8 
levels were assessed by real-time PCR. EPS8 levels are multiplied by 1000 for scaling 
purposes.
Figure 5. Expression levels of HOXA9 targets in primary samples of AML.
(A)  Gene  expression  profiles  for  28  human  primary  AML  patient  samples  were 
downloaded from the www.genome.wi.mit.edu/MPR website.
16 HOXA9 expression levels 
were  used  to  divide  the  samples  into  two  groups.  High  HOXA9  samples  had  pixel 
intensities ranging from 2000-6000 (n=17) and low HOXA9 expressing samples had pixel 
intensity values of 2000 or below (n=11). A Student’s t-test was performed to determine 
which gene expression differences were statistically significant. * = p < 0.05; ** = p < 
0.001.  14 genes whose expression was significantly different between the HOXA9-high 
and  HOXA9-low  groups  of  primary  AML  showed  the  same  direction  of  change  of 
expression as seen in the microarray studies.
 (B) JUNB mRNA levels in high- and low-HOXA9 expressing AML patient samples, as 
measured  by  quantitative  real-time  PCR.  Samples  were  segregated  into  one  of  two 
groups,  based  on  relative  expression  of  HOXA9,  and  normalized  to  GAPDH.  High-
HOXA9 expressing samples had HOXA9/GAPDH ratios of >0.05 (n=4), and low-HOXA9
samples  had  ratios  <0.05  (n=7).  Values  for  JUNB  represent  the  mean  relative 
expression level for each HOXA9 expression group. 
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